Compile Data Set for Download or QSAR
Report error Found 223 Enz. Inhib. hit(s) with all data for entry = 8946
TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandChemical structure of BindingDB Monomer ID 430697BDBM430697(US10544150, Compound 63 | (3-(2-phenylthiazol-4-yl...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandChemical structure of BindingDB Monomer ID 430696BDBM430696(US10544150, Compound 62 | (8-methyl-3-(2-phenylthi...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandChemical structure of BindingDB Monomer ID 430699BDBM430699(US10544150, Compound 65 | (8-methyl-3-(quinolin-2-...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandChemical structure of BindingDB Monomer ID 430698BDBM430698(US10544150, Compound 64 | (8-methyl-3-(2-phenylthi...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandChemical structure of BindingDB Monomer ID 430693BDBM430693(US10544150, Compound 59 | (3-(benzo[d]thiazol-2-yl...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandChemical structure of BindingDB Monomer ID 430692BDBM430692(US10544150, Compound 58 | (3-(2-(2-chlorophenyl)th...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandChemical structure of BindingDB Monomer ID 430695BDBM430695(US10544150, Compound 61 | (4-fluorophenyl)(8-methy...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandChemical structure of BindingDB Monomer ID 430694BDBM430694(US10544150, Compound 60 | (8,8-dimethyl-3-(2-pheny...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandChemical structure of BindingDB Monomer ID 430689BDBM430689(US10544150, Compound 55 | (3-(2-morpholinothiazol-...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandChemical structure of BindingDB Monomer ID 430688BDBM430688(US10544150, Compound 54 | (3-(2-phenylthiazol-4-yl...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandChemical structure of BindingDB Monomer ID 430691BDBM430691(US10544150, Compound 57 | (4-fluorophenyl)(3-(4-ph...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandChemical structure of BindingDB Monomer ID 430690BDBM430690(US10544150, Compound 56 | (8-methyl-3-(2-morpholin...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandChemical structure of BindingDB Monomer ID 430685BDBM430685(US10544150, Compound 51 | (4-fluorophenyl)(8-(2-hy...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandChemical structure of BindingDB Monomer ID 430684BDBM430684(US10544150, Compound 50 | [1,1'-biphenyl]-4-yl(3-(...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandChemical structure of BindingDB Monomer ID 430687BDBM430687(US10544150, Compound 53 | (4'-fluoro-[1,1'-bipheny...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandChemical structure of BindingDB Monomer ID 430686BDBM430686(US10544150, Compound 52 | (4-fluorophenyl)(8-methy...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandChemical structure of BindingDB Monomer ID 430713BDBM430713(US10544150, Compound 79 | [1,1'-biphenyl]-4-yl(3-(...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandChemical structure of BindingDB Monomer ID 430712BDBM430712(US10544150, Compound 78 | (3-(2-(4-fluorophenyl)th...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandChemical structure of BindingDB Monomer ID 430714BDBM430714(US10544150, Compound 80 | (3-(2-(2,4-difluoropheny...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandChemical structure of BindingDB Monomer ID 430708BDBM430708(US10544150, Compound 74 | (3-(2-(2-chlorophenyl)th...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandChemical structure of BindingDB Monomer ID 430711BDBM430711(US10544150, Compound 77 | (3-(2-(2,4-difluoropheny...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandChemical structure of BindingDB Monomer ID 430710BDBM430710(US10544150, Compound 76 | [1,1'-biphenyl]-4-yl(3-(...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandChemical structure of BindingDB Monomer ID 430705BDBM430705(US10544150, Compound 71 | (R)-(4-fluorophenyl)(3-(...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandChemical structure of BindingDB Monomer ID 430704BDBM430704(US10544150, Compound 70 | (4-fluorophenyl)(3-(2-(4...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandChemical structure of BindingDB Monomer ID 430707BDBM430707(US10544150, Compound 73 | (3-(2-(4-fluorophenyl)th...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandChemical structure of BindingDB Monomer ID 430706BDBM430706(US10544150, Compound 72 | [1,1'-biphenyl]-4-yl(8-m...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandChemical structure of BindingDB Monomer ID 430701BDBM430701(US10544150, Compound 67 | [1,1'-biphenyl]-4-yl(3-(...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandChemical structure of BindingDB Monomer ID 430700BDBM430700(US10544150, Compound 66 | (3-(2-(2-chlorophenyl)th...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandChemical structure of BindingDB Monomer ID 430703BDBM430703(US10544150, Compound 69 | (3-(quinolin-2-yl)-5,6-d...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandChemical structure of BindingDB Monomer ID 430702BDBM430702(US10544150, Compound 68 | (R)-(3-(2-(4-chloropheny...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandChemical structure of BindingDB Monomer ID 430729BDBM430729(US10544150, Compound 112 | (4-chloro-3-fluoropheny...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandChemical structure of BindingDB Monomer ID 430728BDBM430728(US10544150, Compound 111 | (3-chloro-4-fluoropheny...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandChemical structure of BindingDB Monomer ID 430731BDBM430731(US10544150, Compound 114 | (8-methyl-3-(2-phenylox...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandChemical structure of BindingDB Monomer ID 430730BDBM430730(US10544150, Compound 113 | (3-(2-(4-fluorophenyl)t...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandChemical structure of BindingDB Monomer ID 430727BDBM430727(US10544150, Compound 110 | (3,4-difluorophenyl)(3-...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandChemical structure of BindingDB Monomer ID 430726BDBM430726(US10544150, Compound 109 | (3,4-dichlorophenyl)(3-...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandChemical structure of BindingDB Monomer ID 430717BDBM430717(US10544150, Compound 90 | (5-phenylpyridin-2-yl)(3...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandChemical structure of BindingDB Monomer ID 430716BDBM430716(US10544150, Compound 85 | (8-methyl-3-(3-phenyl-1,...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandChemical structure of BindingDB Monomer ID 430718BDBM430718(US10544150, Compound 91 | (6-phenylpyridin-3-yl)(3...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandChemical structure of BindingDB Monomer ID 430741BDBM430741(US10544150, Compound 164 | (S)-(4-fluorophenyl)(3-...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandChemical structure of BindingDB Monomer ID 430747BDBM430747(US10544150, Compound 166 | (4-fluorophenyl)(8-meth...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandChemical structure of BindingDB Monomer ID 430746BDBM430746(US10544150, Compound 165 | (S)-(3-(2-(2,4-difluoro...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandChemical structure of BindingDB Monomer ID 430743BDBM430743(US10544150, Compound 162 | (S)-(4-fluorophenyl)(8-...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandChemical structure of BindingDB Monomer ID 430737BDBM430737(US10544150, Compound 136 | (R)-(8-methyl-3-(2-morp...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandChemical structure of BindingDB Monomer ID 430736BDBM430736(US10544150, Compound 135 | (R)-(8-methyl-3-(2-phen...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandChemical structure of BindingDB Monomer ID 50081194BDBM50081194(CHEMBL3422009 | US10544150, Compound 156)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandChemical structure of BindingDB Monomer ID 430738BDBM430738(US10544150, Compound 144 | (R)-(8-methyl-3-(quinol...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandChemical structure of BindingDB Monomer ID 430733BDBM430733(US10544150, Compound 118 | (R)-[1,1'-biphenyl]-4-y...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandChemical structure of BindingDB Monomer ID 430732BDBM430732(US10544150, Compound 115 | (R)-(4-fluorophenyl)(8-...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandChemical structure of BindingDB Monomer ID 430735BDBM430735(US10544150, Compound 134 | (R)-(4'-fluoro-[1,1'-bi...)
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

Displayed 1 to 50 (of 223 total ) | Next | Last >>
Jump to: